|Brand names||Ozidal, Resdone, Ridal, Rispa, Risperdal, Risperon, Rixadone|
Risperidone is an atypical antipsychotic that is on the World Health Organization's List of Essential Medicines and is used to treat schizophrenia, aggression in autism or Alzheimer's disease and bipolar mania.
According to a 2001 review the average monthly weight gain with risperidone is 0.96 kg, making it second least prone to cause weight gain of the 6 atypicals studied in this review, after ziprasidone. It is the most prone of the atypical antipsychotics (SGAs) to causing prolactin elevation (even outpacing some first-generation agents like chlorpromazine and haloperidol), with the exception of its active metabolite, paliperidone; it is also one of the most prone of SGAs for causing movement disorder side effects; it is significantly (statistically at p=0.05) less prone to cause sedation than chlorpromazine, zotepine and clozapine, statistically it is no more prone than other SGAs to cause sedation (although according to the AMH it is more sedating than aripiprazole, and equally sedating to amisulpride, asenapine, chlorpromazine, clozapine, olanzapine and quetiapine).
- NPS MedicineWise List of preparations with information available on them
- NCBI Bookshelf provides free book resources on this topic.
- PubMed provides review articles from the past five years (limit to free review articles or to systematic reviews)
- The TRIP database provides clinical publications about evidence-based medicine.
- TGA-eBS: Ozidal (CMI, PI), Rispa (CMI, PI), Risperdal (CMI, PI), Risperdal Consta (CMI, PI) and others.
- ↑ World Health Organization (October 2013). "WHO Model List of Essential Medicines 18th list" (PDF). who.int. Geneva, Switzerland: World Health Organization. Retrieved 5 September 2014.
- ↑ Brayfield, A, ed. (13 December 2013). "Risperidone". Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press. Retrieved 5 September 2014.
- ↑ Wetterling, T (January 2001). "Bodyweight gain with atypical antipsychotics. A comparative review.". Drug Safety 24 (1): 59–73. PMID 11219487. doi:10.2165/00002018-200124010-00005.
- ↑ Rossi, S, ed. (July 2014). "Comparison of adverse effects of some antipsychotics". Australian Medicines Handbook. Adelaide, Australia: Australian Medicines Handbook Pty Ltd.
- ↑ Leucht, S; Cipriani, A; Spineli, L; Mavridis, D; Orey, D; Richter, F; Samara, M; Barbui, C; Engel, RR; Geddes, JR; Kissling, W; Stapf, MP; Lässig, B; Salanti, G; Davis, JM (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.". Lancet 382 (9896): 951–62. PMID 23810019. doi:10.1016/S0140-6736(13)60733-3.